13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001388551
Total reported value
$1.9M
$1.9M
12 檔
1196.7%
The Q3 2025 SEC filing reveals that Caxton CORP held a total portfolio value of $1.9M, covering 12 public equity positions.
In Q3 2025, Caxton CORP displayed an active expansion posture, initiating 2 new positions and adding to 4 existing holdings, outstripping position reductions.
In terms of portfolio concentration, the top 5 core holdings (including RZLT, GLD, BRK-B) accounted for 1196.7% of total reported equity market value during Q3 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | RZLT | Rezolute Inc | Stock-Other | 81.70% | — | +23.87% | |
| 2 | GLD | Spdr Gold Shares | ETF-Commodities | 11.33% | -81.50% | EXIT | |
| 3 | BRK-B | Berkshire Hathaway Inc-cl B | Stock-Other | 1.43% | +11.69% | +3.01% | |
| 4 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 1.39% | — | -20.73% | |
| 5 | ELVN | Enliven Therapeutics Inc | Stock-Other | 1.17% | — | — | |
| 6 | CMPX | Compass Therapeutics Inc | Stock-Other | 0.82% | — | +23.09% | |
| 7 | BCAX | Bicara Therapeutics Inc | Stock-Other | 0.76% | — | — | |
| 8 | KYTX | Kyverna Therapeutics Inc | Stock-Other | 0.60% | +1.91% | — | |
| 9 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 0.50% | +2.27% | — | |
| 10 | IKT | Inhibikase Therapeutics Inc | Stock-Other | 0.12% | +1.93% | — | |
| 11 | SABS | Sab Biotherapeutics Inc | Stock-Other | 0.10% | — | — | |
| 12 | CNTX | Context Therapeutics Inc | Stock-Other | 0.08% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | RZLT | Rezolute Inc | +6.4% | +23.87% | Add |
| 2 | GLD | Spdr Gold Shares | +4% | +47.13% | Add |
| 3 | CNTX | Context Therapeutics Inc | -0.1% | — | Unchanged |
| 4 | KYTX | Kyverna Therapeutics Inc | -0.3% | — | Unchanged |
| 5 | IKT | Inhibikase Therapeutics Inc | -0.6% | — | Unchanged |
| 6 | LXEO | Lexeo Therapeutics Inc | -0.7% | — | Trim |
| 7 | CMPX | Compass Therapeutics Inc | -0.8% | +23.09% | Add |
| 8 | BCAX | Bicara Therapeutics Inc | -2.1% | — | Unchanged |
| 9 | BRD1EUR | Mind Medicine Mindmed Inc | -2.5% | -20.73% | Trim |
| 10 | BRK-B | Berkshire Hathaway Inc-cl B | -3.5% | +3.01% | Add |
| 11 | ELVN | Enliven Therapeutics Inc | — | NEW | New buy |
| 12 | CRDF | Cardiff Oncology Inc | — | EXIT | Sold out |
| 13 | SABS | Sab Biotherapeutics Inc | — | NEW | New buy |
| 14 | TORCEUR | Adicet Bio Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Caxton CORP reported a total U.S. public equity portfolio value of $1.9M across 12 disclosed positions in Q3 2025.
During Q3 2025, Caxton CORP's top holdings by market value included RZLT (81.7%)、GLD (11.3%)、BRK-B (1.4%). The largest single position, RZLT, represented 81.7% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
ELVN
市值: $268.1K
Top Position Liquidated / Trimmed
CRDF
前期市值: $41.7K
In Q3 2025, Caxton CORP made 10 total portfolio adjustments, initiating 2 new buys, adding to 4 positions, trimming 2 holdings, and fully liquidating 2 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.